NCT07362966

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

RecruitingPHASE4INTERVENTIONAL

Trial Details

Start: 2026-06-06Est. Completion: 2028-05-01

Enrollment target: 120 participants

Locations

General Hospital of Northern Theater Command, Shenyang, Liaoning, China

Contact

Zaixin Jiang, MD, PhDjzxdr2013@163.com +8618646330195

Other microbiome trials you might be interested in

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label TrialPhase 2Recruiting

Chronic Kidney Disease Mineral and Bone DisorderHypertensionDiabetesDyslipidemiaAtherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (Stage 3)

The overall objective of this pilot randomized clinical trial is to determine whether LoDoCo improves vascular disease i…

Dallas, United StatesEst. completion Dec 1, 2027

View Trial →

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and ColchicinePhase 4Recruiting

Coronary Artery Disease

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.